Table 1 Baseline variables and risk of hospitalization
Characteristic | N = 270, n (%) | OR (95% CI) | P-value |
|---|---|---|---|
Patient Characteristics | |||
Agea (years) | |||
Median | 66.6 | 1.0 (1.0–1.0) | 0.80 |
Range | 31–88 | ||
Gender | |||
Female (reference) | 134 (49.6) | ||
Male | 136 (50.4) | 1.1 (0.6–2.1) | 0.69 |
Race | |||
Black (reference) | 76 (28.1) | ||
Caucasian | 168 (62.2) | 1.4 (0.7–2.8) | 0.39 |
Other | 26 (9.6) | 0.10 (0.01–1.8) | 0.12 |
Marital Status | |||
Partnered (reference) | 163 (60.4) | ||
Un-partnered | 107 (39.6) | 0.8 (0.4–1.5) | 0.41 |
Tumor Characteristics | |||
Stage Summary | |||
I-III (reference) | 206 (76.3) | ||
IV | 32 (11.9) | 0.9 (0.3–2.4) | 0.79 |
Loco-regional recurrence | 32 (11.9) | 0.7 (0.2–2.0) | 0.50 |
Histology | |||
Adenocarcinoma (reference) | 144 (53.3) | ||
Squamous cell carcinoma | 88 (32.6) | 1.9 (1.0–3.8) | 0.06 |
Small cell carcinoma | 11 (4.1) | 1.7 (0.4–7.8) | 0.50 |
Other | 27 (10) | 2.0 (0.7–5.4) | 0.12 |
Treatment Characteristics | |||
Concurrent chemo summary | |||
Full Dose (reference) | 141(52.2) | ||
Sensitizing | 93 (34.4) | 1.0 (0.5–1.9) | 0.89 |
No chemo | 36 (13.3) | 0.4 (0.1–1.4) | 0.17 |
Baseline Frailty Markers | |||
ECOG PSa | N = 257 | ||
Median | 1 | 1.7 (1.0–2.9) | 0.07 |
Range | 0–3 | ||
CCIa | N = 270 | ||
Median | 5 | 1.0 (0.9–1.2) | 0.73 |
Range | 2–16 | ||
Patient reported weight loss | N = 269 | ||
No (reference) | 100 (37.2) | ||
Yes | 169 (62.8) | 1.0 (0.5–1.8) | 0.90 |
BMI (kg/m2) | N = 270 | ||
> 20 (reference) | 244 (90.4) | ||
≤ 20 | 26 (9.6) | 1.9 (0.8–4.9) | 0.16 |
Hemoglobin (g/dL) | N = 259 | ||
> 10 (reference) | 233 (90.0) | ||
≤ 10 | 26 (10.0) | 3.3 (1.4–7.9) | 0.01 |
Creatinine (mg/dL) | N = 258 | ||
≤ 1.1 (reference) | 206 (79.8) | ||
> 1.1 | 52 (20.2) | 1.1 (0.5–2.3) | 0.91 |
Albuminb (g/dL) | N = 254 | ||
Median | 3.7 | 3.1 (1.6–5.9) | < 0.01 |
Range | 2.3–4.8 | ||